306 related articles for article (PubMed ID: 25543678)
1. Advances in pharmacotherapy for primary biliary cirrhosis.
Mousa HS; Lleo A; Invernizzi P; Bowlus CL; Gershwin ME
Expert Opin Pharmacother; 2015 Apr; 16(5):633-43. PubMed ID: 25543678
[TBL] [Abstract][Full Text] [Related]
2. Mechanism-based target therapy in primary biliary cholangitis: opportunities before liver cirrhosis?
Yang Y; He X; Rojas M; Leung PSC; Gao L
Front Immunol; 2023; 14():1184252. PubMed ID: 37325634
[TBL] [Abstract][Full Text] [Related]
3. Exploring Advanced Therapies for Primary Biliary Cholangitis: Insights from the Gut Microbiota-Bile Acid-Immunity Network.
Guo Z; He K; Pang K; Yang D; Lyu C; Xu H; Wu D
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673905
[TBL] [Abstract][Full Text] [Related]
4. Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis.
Ao X; Zeng Y; Wang X; Fan X
Aliment Pharmacol Ther; 2024 Jul; 60(1):105-106. PubMed ID: 38803269
[No Abstract] [Full Text] [Related]
5. Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis-Authors' reply.
Burghart L; Hofer BS; Halilbasic E; Simbrunner B; Staettermayer AF; Trauner M; Reiberger T
Aliment Pharmacol Ther; 2024 Jul; 60(1):107-108. PubMed ID: 38803242
[No Abstract] [Full Text] [Related]
6. Novel therapeutic targets in primary biliary cirrhosis.
Dyson JK; Hirschfield GM; Adams DH; Beuers U; Mann DA; Lindor KD; Jones DE
Nat Rev Gastroenterol Hepatol; 2015 Mar; 12(3):147-58. PubMed ID: 25645973
[TBL] [Abstract][Full Text] [Related]
7. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.
Nevens F; Andreone P; Mazzella G; Strasser SI; Bowlus C; Invernizzi P; Drenth JP; Pockros PJ; Regula J; Beuers U; Trauner M; Jones DE; Floreani A; Hohenester S; Luketic V; Shiffman M; van Erpecum KJ; Vargas V; Vincent C; Hirschfield GM; Shah H; Hansen B; Lindor KD; Marschall HU; Kowdley KV; Hooshmand-Rad R; Marmon T; Sheeron S; Pencek R; MacConell L; Pruzanski M; Shapiro D;
N Engl J Med; 2016 Aug; 375(7):631-43. PubMed ID: 27532829
[TBL] [Abstract][Full Text] [Related]
8. Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy.
Purohit T; Cappell MS
World J Hepatol; 2015 May; 7(7):926-41. PubMed ID: 25954476
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the development of farnesoid X receptor agonists.
Ali AH; Carey EJ; Lindor KD
Ann Transl Med; 2015 Jan; 3(1):5. PubMed ID: 25705637
[TBL] [Abstract][Full Text] [Related]
10. Network meta-analysis of randomized controlled trials: efficacy and safety of UDCA-based therapies in primary biliary cirrhosis.
Zhu GQ; Shi KQ; Huang S; Huang GQ; Lin YQ; Zhou ZR; Braddock M; Chen YP; Zheng MH
Medicine (Baltimore); 2015 Mar; 94(11):e609. PubMed ID: 25789951
[TBL] [Abstract][Full Text] [Related]
11. Fibrates and cholestasis.
Ghonem NS; Assis DN; Boyer JL
Hepatology; 2015 Aug; 62(2):635-43. PubMed ID: 25678132
[TBL] [Abstract][Full Text] [Related]
12. Therapy of Primary Biliary Cirrhosis: Novel Approaches for Patients with Suboptimal Response to Ursodeoxycholic Acid.
Parés A
Dig Dis; 2015; 33 Suppl 2():125-33. PubMed ID: 26642350
[TBL] [Abstract][Full Text] [Related]
13. Obeticholic acid for the treatment of primary biliary cirrhosis.
Trivedi PJ; Hirschfield GM; Gershwin ME
Expert Rev Clin Pharmacol; 2016; 9(1):13-26. PubMed ID: 26549695
[TBL] [Abstract][Full Text] [Related]
14. Primary biliary cirrhosis.
Carey EJ; Ali AH; Lindor KD
Lancet; 2015 Oct; 386(10003):1565-75. PubMed ID: 26364546
[TBL] [Abstract][Full Text] [Related]
15. Novel Aspects in the Management of Cholestatic Liver Diseases.
Chazouillères O
Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
[TBL] [Abstract][Full Text] [Related]
16. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond.
Beuers U; Trauner M; Jansen P; Poupon R
J Hepatol; 2015 Apr; 62(1 Suppl):S25-37. PubMed ID: 25920087
[TBL] [Abstract][Full Text] [Related]
17. Obeticholic acid for the treatment of primary biliary cholangitis.
Ali AH; Lindor KD
Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
[TBL] [Abstract][Full Text] [Related]
18. Targeting the FXR nuclear receptor to treat liver disease.
Neuschwander-Tetri BA
Gastroenterology; 2015 Apr; 148(4):704-6. PubMed ID: 25724453
[No Abstract] [Full Text] [Related]
19. Proposed therapies in primary biliary cholangitis.
Floreani A; Sun Y; Zou ZS; Li B; Cazzagon N; Bowlus CL; Gershwin ME
Expert Rev Gastroenterol Hepatol; 2016; 10(3):371-382. PubMed ID: 26577047
[TBL] [Abstract][Full Text] [Related]
20. Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy.
Lammers WJ; Hirschfield GM; Corpechot C; Nevens F; Lindor KD; Janssen HL; Floreani A; Ponsioen CY; Mayo MJ; Invernizzi P; Battezzati PM; Parés A; Burroughs AK; Mason AL; Kowdley KV; Kumagi T; Harms MH; Trivedi PJ; Poupon R; Cheung A; Lleo A; Caballeria L; Hansen BE; van Buuren HR;
Gastroenterology; 2015 Dec; 149(7):1804-1812.e4. PubMed ID: 26261009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
